0000000000014315

AUTHOR

Clare Peckitt

showing 10 related works from this author

Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advan…

2014

3575 Background: After the use of preoperative radiotherapy and TME, survival of LARC has reached a plateau. More effective therapies, predictive/prognostic factors for treatment selection and vali...

OncologyCancer Researchmedicine.medical_specialtyChemotherapyPreoperative radiotherapybusiness.industryColorectal cancermedicine.medical_treatmentLocally advancedmedicine.diseaseSurgeryPooled analysisOncologyInternal medicinemedicinesense organsbusinessChemoradiotherapyJournal of Clinical Oncology
researchProduct

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial

2015

KRAS mutation has been reported as a marker of radio-resistance in rectal cancer and unfavourable outcome in both colon and rectal cancer. This study suggests that a single-nucleotide polymorphism of the KRAS gene (LCS-6 variant) may predict response to neoadjuvant treatment and mitigate the poor prognosis associated with KRAS mutation in locally advanced rectal cancer.

MaleOncologyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentLET-7 MICRORNA-BINDINGCetuximabmedicine.disease_causeCOLORECTAL-CANCER3'-UNTRANSLATED REGION0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsRectal cancerNeoadjuvant therapySingle-nucleotide polymorphism0303 health sciencesCetuximabCOLON-CANCERHazard ratioCAPOX RegimenChemoradiotherapyHematologysingle-nucleotide polymorphismMiddle AgedCombined Modality TherapyNeoadjuvant TherapyBINDING SITE POLYMORPHISM3. Good healthOxaliplatinLet-7Oncology030220 oncology & carcinogenesis5-FLUOROURACIL/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemaleKRASLife Sciences & Biomedicinemedicine.drugAdultGenetic Markersmedicine.medical_specialtyGenotypeLCS-6 KRAS variantPolymorphism Single NucleotideDisease-Free SurvivalCLINICAL-TRIALProto-Oncogene Proteins p21(ras)03 medical and health sciencesSDG 3 - Good Health and Well-beinglet-7Internal medicineGastrointestinal TumorsBiomarkers TumorKRASmedicineHumansOncology & CarcinogenesisProgression-free survivalrectal cancerneoplasmsCapecitabineAged030304 developmental biologyCancer och onkologiScience & TechnologyRectal Neoplasmsbusiness.industryOriginal Articlesmedicine.diseasedigestive system diseasesMicroRNAsCancer and Oncologybusiness1112 Oncology And CarcinogenesisChemoradiotherapyRASAnnals of Oncology
researchProduct

FcγRIIa and Fc γ RIIIa Polymorphisms and Cetuximab Benefit in the Microscopic Disease

2014

Abstract Purpose: FcγR polymorphisms have been reported to enhance the immune-mediated effects of cetuximab in metastatic colorectal cancer. There are no data on the relationship between these polymorphisms and cetuximab in the early-stage setting. We performed a pharmacogenomic analysis of EXPERT-C, a randomized phase II trial of neoadjuvant CAPOX followed by chemoradiotherapy, surgery, and adjuvant CAPOX ± cetuximab in high-risk, locally advanced rectal cancer. Experimental Design: FcγRIIa-H131R and FcγRIIIa-V158F polymorphisms were analyzed on DNA from peripheral blood samples. Kaplan–Meier method and Cox regression analysis were used to calculate survival estimates and compare treatment…

OncologyCancer Researchmedicine.medical_specialtyPrognostic variableGenotypeColorectal cancermedicine.medical_treatmentCetuximabAntibodies Monoclonal HumanizedDisease-Free SurvivalInternal medicineGenotypemedicineHumansGenotypingCetuximabProportional hazards modelbusiness.industryReceptors IgGPrognosismedicine.diseaseErbB ReceptorsTreatment OutcomeOncologyImmunologyColorectal NeoplasmsbusinessAdjuvantChemoradiotherapymedicine.drugClinical Cancer Research
researchProduct

Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients

2016

Summary Analysis of a polymorphism in mature microRNA-608 (rs4919510) in rectal cancer patients enrolled in a randomized phase II clinical trial identified patient subpopulations who might benefit from the use of an intensified neo-adjuvant treatment strategy with Cetuximab.

AdultMale0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyPathologyGenotypeColorectal cancermedicine.medical_treatmentOriginal ManuscriptSingle-nucleotide polymorphismPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmicroRNAmedicineHumansOncology & CarcinogenesisProgression-free survivalNeoadjuvant therapyAgedRetrospective StudiesCetuximabRectal Neoplasmsbusiness.industryChemoradiotherapyGeneral MedicineMiddle Agedmedicine.diseaseChemotherapy regimenNeoadjuvant Therapy3. Good healthRadiation therapyMicroRNAs030104 developmental biology030220 oncology & carcinogenesisFemalebusiness1112 Oncology And Carcinogenesismedicine.drug
researchProduct

Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer

2017

Background: Limited data exist regarding the correlation between MRI tumour regression grade (mrTRG) and pathological TRG (pTRG) in rectal cancer. Methods: mrTRG and pTRG were compared in rectal cancer patients from two phase II trials (EXPERT and EXPERT-C). The agreement between radiologist and pathologist was assessed with the weighted κ test while the Kaplan–Meier method was used to estimate survival outcomes. Results: One hundred ninety-one patients were included. Median time from completion of neoadjuvant treatment to pre-operative MRI and surgery was 4.1 weeks (interquartile range (IQR): 3.7–4.7) and 6.6 weeks (IQR: 5.9–7.6), respectively. Fair agreement was found between mrTRG and pT…

MaleCancer ResearchPathologySURGERYColorectal cancerACCURACYmedicine.medical_treatmentMagnetic resonance tumour regression gradePREOPERATIVE CHEMORADIATIONKaplan-Meier EstimateTHERAPY030218 nuclear medicine & medical imaging0302 clinical medicineInterquartile rangeRectal cancerNeoadjuvant therapyAged 80 and overCOMPLETE RESPONSEmedicine.diagnostic_testMiddle AgedMagnetic Resonance ImagingNeoadjuvant TherapyOncology030220 oncology & carcinogenesisFemaleRadiologyLife Sciences & BiomedicineRADIOTHERAPYAdultmedicine.medical_specialtyCytodiagnosismagnetic resonance tumour regression gradeDisease-Free Survival03 medical and health sciencesClinical Trials Phase II as TopicmedicinePathological tumour regression gradeHumansOncology & Carcinogenesisrectal cancerPathologicalpathological tumour regression gradeAgedNeoplasm StagingScience & TechnologyRectal Neoplasmsbusiness.industryTOTAL MESORECTAL EXCISIONMagnetic resonance imagingChemoradiotherapy AdjuvantRANDOMIZED PHASE-IIINEOADJUVANT CHEMORADIOTHERAPYmedicine.diseaseClinical trialRadiation therapyClinical StudyFOLLOW-UPbusiness1112 Oncology And CarcinogenesisChemoradiotherapy
researchProduct

FCγRIIa and FCγRIIIa polymorphisms (SNPs) and cetuximab (C) benefit in the EXPERT-C trial.

2014

3573 Background: FCγRIIa-H131R and FCγRIIIa-V158F SNPs have been reported to enhance the immune-mediated effects of monoclonal antibodies including cetuximab (C) in metastatic colorectal cancer (CR...

OncologyCancer Researchmedicine.medical_specialtyCetuximabmedicine.drug_classColorectal cancerbusiness.industrySingle-nucleotide polymorphismBioinformaticsMonoclonal antibodymedicine.diseasedigestive system diseasesOncologyInternal medicinemedicinebusinessmedicine.drugJournal of Clinical Oncology
researchProduct

HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and che…

2013

HER2 is an established therapeutic target in breast and gastric cancers. The role of HER2 in rectal cancer is unclear, as conflicting data on the prevalence of HER2 expression in this disease have been reported. We evaluated the prevalence of HER2 and its impact on the outcome of high-risk rectal cancer patients treated with neoadjuvant CAPOX and CRT +/- cetuximab in the EXPERT-C trial. Eligible patients with available tumour tissue for HER2 analysis were included. HER2 expression was determined by immunohistochemistry (IHC) in pre-treatment biopsies and/or surgical specimens (score 0-3+). Immunostaining was scored according to the consensus panel recommendations on HER2 scoring for gastric…

OncologyAdultMalemedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancerReceptor ErbB-2medicine.medical_treatmentCetuximabAdenocarcinomamedicine.disease_causeAntibodies Monoclonal HumanizedDeoxycytidineDisease-Free SurvivalCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSingle-Blind Methodskin and connective tissue diseasesneoplasmsNeoadjuvant therapyCapecitabineAgedProportional Hazards ModelsRetrospective StudiesCetuximabbusiness.industryRectal NeoplasmsCancerCAPOX RegimenHematologyChemoradiotherapyMiddle Agedmedicine.diseaseNeoadjuvant TherapyOxaliplatinTreatment OutcomeOncologyChemotherapy AdjuvantFemaleKRASFluorouracilbusinessChemoradiotherapymedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer

2016

This analysis confirms that administering neoadjuvant chemotherapy (NACT) before chemoradiotherapy (CRT) could be a potential option for high-risk, locally advanced rectal cancer. In this setting, MRI tumour regression grade is an independent prognostic factor and, when assessed after NACT, may predict the probability and magnitude of incremental benefit from sequential CRT.EXPERT and EXPERT-C were phase II clinical trials of neoadjuvant chemotherapy (NACT) followed by chemoradiotherapy (CRT) in high-risk, locally advanced rectal cancer (LARC). We pooled individual patient data from these trials. The primary objective was overall survival (OS) in the intention-to-treat (ITT) population. Pro…

AdultMale0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatmentPopulationPhases of clinical researchKaplan-Meier EstimateDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansProgression-free survivalStage (cooking)educationNeoadjuvant therapyAgedAged 80 and overeducation.field_of_studyIntention-to-treat analysisRectal Neoplasmsbusiness.industrySurrogate endpointChemoradiotherapyHematologyMiddle AgedMagnetic Resonance ImagingNeoadjuvant TherapyTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalbusinessChemoradiotherapy
researchProduct

RAS mutations and cetuximab in locally advanced rectal cancer: Results of the EXPERT-C trial

2013

Background: RAS mutations predict resistance to anti-epidermal growthfactor receptor (EGFR) monoclonal antibodies in metastatic colorectal cancer. We analysed RAS mutations in 30 non-metastatic rectal cancer patients treated with or without cetuximab within the 31 EXPERT-C trial. Methods: Ninety of 149 patients with tumours available for analysis were KRAS/BRAF wild-type, and randomly assigned to capecitabine plus oxaliplatin (CAPOX) followed by chemoradiotherapy, surgery and adjuvant CAPOX or the same regimen plus cetuximab (CAPOX-C). Of these, four had a mutation of NRAS exon 3, and 84 were retrospectively analysed for additional KRAS (exon 4) and NRAS (exons 2/4) mutations by using bi-di…

AdultMaleOncologyNeuroblastoma RAS viral oncogene homologCancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancerPopulationCetuximabAntibodies Monoclonal Humanizedmedicine.disease_causeDeoxycytidineCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumanseducationneoplasmsCapecitabineAgedRetrospective Studieseducation.field_of_studyCetuximabRectal Neoplasmsbusiness.industryChemoradiotherapySequence Analysis DNAMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseasesOxaliplatinOxaliplatinTreatment OutcomeOncologyMutationras ProteinsFemaleFluorouracilKRASbusinessChemoradiotherapymedicine.drugEuropean Journal of Cancer
researchProduct

Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Inten…

2015

Objective Intensified preoperative treatments have been increasingly investigated in locally advanced rectal cancer (LARC), but limited data are available for the impact of these regimens on quality of life (QoL) and bowel function (BF). We assessed these outcome measures in EXPERT-C, a randomized phase 2 trial of neoadjuvant capecitabine combined with oxaliplatin (CAPOX), followed by chemoradiation therapy (CRT), total mesorectal excision, and adjuvant CAPOX with or without cetuximab in magnetic resonance imaging-defined, high-risk LARC. Methods and Materials QoL was assessed using the European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-CR29 questionnaires. Bowel inc…

Cancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancerHealth StatusCetuximabAntineoplastic AgentsUrinary incontinenceBowel incontinenceSeverity of Illness Indexlaw.inventionRandomized controlled trialQuality of lifelawSurveys and QuestionnairesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansFecal incontinenceRadiology Nuclear Medicine and imagingSexual Dysfunctions PsychologicalCapecitabineRadiationRectal Neoplasmsbusiness.industryRectumChemoradiotherapy Adjuvantmedicine.diseaseMagnetic Resonance ImagingTotal mesorectal excisionNeoadjuvant TherapyhumanitiesSurgeryOxaliplatinOncologyChemotherapy AdjuvantQuality of Lifemedicine.symptombusinessFecal IncontinenceChemoradiotherapyInternational Journal of Radiation Oncology*Biology*Physics
researchProduct